The primary purpose of this study is to preliminarily estimate the efficacy of psilocybin-facilitated treatment for fibromyalgia.
Investigators will assess the impact of psilocybin-facilitated treatment on pain, fatigue, and other fibromyalgia symptoms, in addition to the level of functioning and quality of life.
Investigators will also evaluate potential mediators of treatment (e.g., treatment expectations, pain characteristics, personality, beliefs/cognitions, emotions). Investigators hypothesize psilocybin treatment will significantly reduce symptom severity in fibromyalgia patients.
Topic Fibromyalgia
Pain
Compound Placebo
Psilocybin
Country United States of America
Visit trial
Status
Not yet recruiting
Results Published
Start date
01 January 2022
End date
01 July 2024
Chance of happening
88%
Phase
Phase II
Design
Blinded
Type
Interventional
Generation
First
Participants
30
Sex
Female
Age
25- 65
Therapy
No
Trial Details
The primary purpose of this study is to preliminarily estimate the efficacy of psilocybin-facilitated treatment for fibromyalgia. Investigators will assess the impact of psilocybin-facilitated treatment on pain, fatigue, and other fibromyalgia symptoms, in addition to the level of functioning and quality of life. Investigators will also evaluate potential mediators of treatment (e.g., treatment expectations, pain characteristics, personality, beliefs/cognitions, emotions). Investigators hypothesize psilocybin treatment will significantly reduce symptom severity in fibromyalgia patients.NCT Number NCT05068791
Sponsors & Collaborators
University of AlabamaResearchers at the University of Alabama are investigating the potential use of psychedelics in a number of disorders.